Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | LRAT | O95237 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GJA1 | P17302 | 1/20 | 0.39 |
| ▸ | GJB2 | P29033 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20713592 | 1.00 | L3MBTL1 (0.51) | L3MBTL1MAPTLMNAKDM4EALOX15 | |
| SCHEMBL20713636 | 1.00 | L3MBTL1 (0.51) | L3MBTL1MAPTLMNAKDM4EALOX15 | |
| SCHEMBL22639646 | 1.00 | L3MBTL1 (0.51) | L3MBTL1MAPTLMNAKDM4EALOX15 | |
| SCHEMBL16688093 | 1.00 | L3MBTL1 (0.51) | L3MBTL1MAPTLMNAKDM4EALOX15 | |
| SCHEMBL16577216 | 1.00 | L3MBTL1 (0.51) | L3MBTL1MAPTLMNAKDM4EALOX15 | |
| SCHEMBL16589049 | 1.00 | L3MBTL1 (0.51) | L3MBTL1MAPTLMNAKDM4EALOX15 | |
| SCHEMBL23743113 | 0.91 | L3MBTL1 (0.44) | L3MBTL1MAPTLMNAKDM4EALOX15 | |
| SCHEMBL22429030 | 0.87 | L3MBTL1 (0.42) | L3MBTL1MAPTLMNAKDM4EALOX15 | |
| SCHEMBL15459182 | 0.86 | LRAT (0.50) | LMNAKDM4EALOX15TSHRHSD17B10 | |
| SCHEMBL15459179 | 0.86 | L3MBTL1 (0.51) | L3MBTL1MAPTLMNAKDM4EALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067672-A1 | FLAVONE DERIVATIVE FOR TREATING TUMORS AND USE THEREOF | SICHUAN FUSHENGYUAN TECHNOLOGY CO., LTD (CN) | 2024-02-29 | — | — | US | disclosed |
| US-9403857-B2 | Compositions and methods for the treatment of metabolic syndrome | CELLIX BIO PRIVATE LIMITED (IN) | 2016-08-02 | — | — | US | disclosed |
| US-9321716-B1 | Compositions and methods for the treatment of metabolic syndrome | CELLIX BIO PRIVATE LIMITED (IN) | 2016-04-26 | — | — | US | disclosed |
| US-9315478-B2 | Compositions and methods for the treatment of metabolic syndrome | CELLIX BIO PRIVATE LIMITED (IN) | 2016-04-19 | — | — | US | disclosed |
| US-20150126497-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME | CELLIX BIO PRIVATE LIMITED (IN) | 2015-05-07 | — | — | US | disclosed |
| US-20150087660-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC DISEASES AND INFLAMMATORY DISORDERS | KANDULA MAHESH (IN) | 2015-03-26 | — | — | US | disclosed |
| US-20150080345-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME | CELLIX BIO PRIVATE LIMITED (IN) | 2015-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067672-A1 | FLAVONE DERIVATIVE FOR TREATING TUMORS AND USE THEREOF | TPD52L2, F12, H1-0 | L3MBTL1 216/4885MAPT 4763/4885LMNA 2178/4885 |
| US-20150080345-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME | FABP4, GYS2, FABP2 | L3MBTL1 3881/4885MAPT 830/4885LMNA 2634/4885 |
| US-20150087660-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC DISEASES AND INFLAMMATORY DISORDERS | IL1B, IAPP, CXCL12 | L3MBTL1 3809/4885MAPT 852/4885LMNA 1389/4885 |
| US-20150126497-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME | SLC5A1, IRS1, SLC5A2 | L3MBTL1 1780/4885MAPT 1018/4885LMNA 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.